ESMC ESCALON MEDICAL CORP
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 862668 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.4%
TTM net income YoY4,528.3%
TTM EPS YoY1,700.0%
Revenue 3-yr CAGR3.2%
Net income 3-yr CAGR81.5%
Margins
Gross margin44.1%
Operating margin3.8%
Net margin32.8%
FCF margin0.8%
EBITDA margin3.9%
Returns
ROE114.9%
ROA61.7%
ROIC (approx.)22.8%
Asset turnover1.88x
Leverage & solvency
Liabilities / assets38.4%
Debt / equity0.00x
Current ratio2.72x
Interest coverage149.58x
Cash quality & payout
Operating cash flow / net income0.03x
Accruals ratio60.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.71M | $3.86M | $2.61M | $3.59M | $2.68M | $2.57M | $3.47M | $3.22M |
| Cost of revenue | $2.08M | $1.91M | $1.66M | $2.04M | $1.55M | $1.45M | $1.87M | $1.65M |
| Gross profit | $1.63M | $1.95M | $946,662 | $1.56M | $1.12M | $1.12M | $1.60M | $1.57M |
| R&D expense | $94,398 | $124,300 | $29,908 | $131,182 | $216,098 | $291,576 | $164,755 | $155,940 |
| SG&A expense | $1.27M | $1.25M | $1.34M | $1.33M | $1.11M | $1.20M | $1.16M | $1.16M |
| Operating income | $269,548 | $568,511 | -$419,263 | $98,738 | -$202,751 | -$371,769 | $276,037 | $255,904 |
| Interest expense | $305 | -$825 | $3,204 | $776 | $4,304 | $7,982 | $4,565 | $4,883 |
| Income tax | $0 | -$1.14M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $269,243 | $1.78M | $2.37M | $97,677 | -$239,852 | -$379,751 | $271,472 | $246,021 |
| EBITDA | $272,548 | $571,512 | -$416,263 | $107,155 | -$194,581 | -$363,217 | $284,825 | $265,756 |
| EPS (basic) | 0.02 | — | 0.16 | 0.01 | -0.03 | — | 0.02 | 0.02 |
| EPS (diluted) | 0.02 | — | 0.16 | 0.01 | -0.03 | — | 0.02 | 0.02 |
| Weighted avg. shares (diluted) | 14.19M | — | 14.51M | 14.42M | 7.42M | — | 14.17M | 14.08M |
| Banking | ||||||||
| Provision for credit losses | $126 | — | — | — | -$89,322 | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.67M | $3.07M | $3.34M | $337,434 | $615,791 | $545,835 | $540,908 | $520,584 |
| Receivables | $1.91M | $1.90M | $1.34M | $2.24M | $1.34M | $1.50M | — | — |
| Inventory | $1.84M | $1.73M | $1.66M | $1.52M | $1.75M | $2.14M | $1.74M | $1.72M |
| Current assets | $7.70M | $7.01M | $6.57M | $4.29M | $4.22M | $4.61M | $4.84M | $4.30M |
| PP&E, net | $23,694 | $26,605 | $29,516 | $32,427 | $35,752 | $34,589 | $34,348 | $38,224 |
| Intangibles | $8,045 | $8,134 | $8,224 | $19,788 | $24,880 | $29,792 | $34,705 | $39,617 |
| Total assets | $10.07M | $9.13M | $7.53M | $4.98M | $4.58M | $4.99M | $5.22M | $4.49M |
| Current liabilities | $2.83M | $2.39M | $2.53M | $2.60M | $2.53M | $2.69M | $2.52M | $2.21M |
| Total liabilities | $3.87M | $3.20M | $3.39M | $3.21M | $2.91M | $3.08M | $2.92M | $2.46M |
| Shareholders' equity | $6.20M | $5.93M | $4.15M | $1.77M | $1.68M | $1.92M | $2.29M | $2.02M |
| Shares outstanding | 7.42M | 7.42M | 7.42M | 7.42M | — | 7.42M | 7.42M | 7.42M |
| Cash flow statement | ||||||||
| Operating cash flow | $603,173 | -$251,180 | $280,983 | -$517,415 | $85,008 | $15,760 | $30,695 | $300,941 |
| Capital expenditure | $0 | $0 | $0 | $0 | $4,421 | $3,880 | $0 | $0 |
| Free cash flow | $603,173 | -$251,180 | $280,983 | -$517,415 | $80,587 | $11,880 | $30,695 | $300,941 |
| Investing cash flow | $0 | -$25,000 | $2.83M | $0 | -$4,421 | -$3,880 | $0 | $0 |
| Financing cash flow | -$883 | -$889 | -$100,880 | -$17,524 | -$10,599 | -$6,921 | -$10,339 | -$10,021 |
| Depreciation & amortization | $3,000 | $3,001 | $3,000 | $8,417 | $8,170 | $8,552 | $8,788 | $9,852 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.